8-K: Biote Corp. Aims to Transform Healthy Aging with Therapeutic Wellness Expansion

Biote Corp. is leveraging its hormone optimization leadership to expand into the therapeutic wellness market, targeting a substantial addressable market with its technology-driven platform.

Summary

• Biote Corp. is focused on transforming healthy aging by expanding its services beyond hormone optimization into the broader therapeutic wellness market.
• The company aims to become a single-source provider of evidence-based therapeutic wellness solutions, leveraging its existing technology, training platform, and clinical expertise.
• In 2024, Biote reported revenue of $197.2 million and adjusted EBITDA of $58.2 million, with a 29.5% adjusted EBITDA margin.
• The company has provided 2025 revenue guidance of $202 million to $208 million and adjusted EBITDA guidance of $59 million to $64 million.
• Biote is focused on strategic investments, including share repurchases and potential acquisitions, to drive growth and enhance capabilities.
• The company is prioritizing maximizing value from top-tier providers, leveraging clinical decision support software, developing differentiated offerings, and adding new practitioners.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Biote, highlighting its growth strategy, market opportunity, and financial performance. While there are some risks and challenges, the overall tone is optimistic.

Positives

• Biote is the established leader in hormone optimization with a strong network of certified practitioners.
• The company has a growing, profitable, and capital-light business model.
• Biote's technology, clinical, education, and training platform distinguishes the brand.
• The company has a significant geographic and practitioner expansion opportunity.
• Biote's scalable and proprietary platform drives clinic success and retention.
• The company is committed to research and has a leading voice in training and education.
• Biote has a strong balance sheet and is generating solid cash flow.

Negatives

• Q1 2025 adjusted EBITDA is expected to be approximately 5% lower compared to Q1 2024.
• Implementing changes to drive revenue growth and improve consistency may take time to show results.
• The company faces significant competition in the therapeutic wellness market.
• The company's success depends on the acceptance of its dietary supplements and the reliability of third-party hormone manufacturers.

Risks

• The success of dietary supplements depends on market acceptance among clinics, practitioners, and patients.
• Reliance on third parties for bio-identical hormone manufacturing poses a risk.
• Regulatory, economic, environmental, and competitive conditions could impact the company's performance.
• The company's ability to increase the use of the Biote Method by practitioners and clinics is uncertain.
• The company faces significant competition in its industry.
• The company's limited operating history and ability to protect its intellectual property are risks.
• Changes in applicable laws or regulations and international tariffs could adversely impact the company.
• The company may be adversely impacted by economic, business, and/or competitive factors, including natural disasters.
• Future exchange and interest rates could impact the company's performance.

Future Outlook

Biote anticipates revenue between $202 million and $208 million and adjusted EBITDA between $59 million and $64 million for 2025. Revenue is expected to be slightly higher in Q1 2025 compared to Q1 2024, while adjusted EBITDA is expected to be approximately 5% lower.

Management Comments

• The company is confident in its ability to create a stronger commercial organization with increased productivity later this year.

Industry Context

Biote's expansion into therapeutic wellness aligns with the growing consumer interest in personal health and wellness, as well as the trend toward preventive medicine. The therapeutic wellness market is estimated to be over $400 billion, with a 5-10% CAGR.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the document does mention that the hormone replacement market is $7B+ with a 7% CAGR.
• The document also mentions that 82% of US Consumers Consider US Therapeutic Wellness a Top or Important Wellness Priority in their Everyday Lives.

Stakeholder Impact

• Shareholders: The company's growth strategy and share repurchase program are intended to enhance shareholder value.
• Practitioners: Biote's platform and training programs are designed to support practitioners and enhance their clinic economics.
• Patients: Biote aims to provide evidence-based therapeutic wellness solutions to improve patient health and quality of life.

Next Steps

• Strengthen efforts to maximize value from top-tier providers.
• Fully leverage the capabilities of enhanced clinical decision support software.
• Continue to develop more high-value and differentiated offerings for practitioners and patients.
• Intensify focus on adding new practitioners.
• Drive revenue growth by strengthening accountability and improving consistency and discipline.

Key Dates